NCT07157124 Examining the Effectiveness of Dynamic Visual Noise (DVN) for Reducing Alcohol Cravings and Consumption in College Students
| NCT ID | NCT07157124 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Wyoming |
| Condition | Craving |
| Study Type | INTERVENTIONAL |
| Enrollment | 62 participants |
| Start Date | 2025-09-22 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 62 participants in total. It began in 2025-09-22 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to examine whether dynamic visual noise (DVN), a short video array of rapidly moving black and white squares, reduces cravings for and consumption of alcohol in college students who drink alcohol and experience cravings for alcohol at least once a week on average. A second goal of this clinical trial is to examine whether changes in attentional bias towards alcohol (that is, the tendency to pay greater mental and visual attention towards alcohol over other things in one's environment) is a mechanism by which DVN reduces alcohol cravings and consumption. Researchers will compare DVN to static visual noise (SVN), which is a still image of black and white squares that has been used as a control condition for DVN in prior literature. Participants will: 1. Visit the laboratory once to complete the baseline data collection 2. Watch the DVN or SVN every day for seven days (including the day of the laboratory visit) 3. Complete daily follow-ups for six days following the day of the laboratory visit 4. Complete a final follow-up on the seventh day following the laboratory visit
Eligibility Criteria
Inclusion Criteria: 1. Must report being between the age of 18 and 29 2. Must report drinking alcohol at least once per week on average over the past month 3. Must report having drank beer or alcoholic seltzers in the past month 4. Must endorse experiencing craving at least once per week over the past month, on average 5. Must report not currently receiving nor planning to seek any other treatment for their alcohol use within the next 30 days 6. Must report owning a personal electronic device with access to the Internet 7. Must report owning or having access to a computer with access to the Internet Exclusion Criteria: 1. Major visual impairment (i.e., legal blindness or color blindness) 2. History of seizures and/or diagnosed seizure disorder 3. Current medical diagnosis provided by a qualified professional (i.e., psychologist, psychiatrist, neurologist) that is characterized by cognitive impairment (i.e., neurocognitive disorder due to traumatic brain injury, traumatic brain injury, HIV infection, post-concussive syndrome, and intellectual disability) 4. Concussion in the past month 5. A current diagnosis of any substance use disorder besides alcohol use disorder, as determined by a qualified professional (i.e., psychologist, psychiatrist)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07157124 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 29 Years, studying Craving. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07157124 currently recruiting?
Yes, NCT07157124 is actively recruiting participants. Contact the research team at ewinterl@uwyo.edu for enrollment information.
Where is the NCT07157124 trial being conducted?
This trial is being conducted at Laramie, United States.
Who is sponsoring the NCT07157124 clinical trial?
NCT07157124 is sponsored by University of Wyoming. The trial plans to enroll 62 participants.